Editas Medicine

Company Overview

Editas Medicine is a leading clinical-stage gene editing company using CRISPR/Cas9 and CRISPR/Cas12a systems to develop transformative treatments for severe diseases. The company aims to discover, develop, manufacture, and commercialize precise, durable genomic medicines. Its platform targets nearly any gene, expanding treatment options for ocular, blood, and cancer diseases. Editas focuses on both in vivo gene editing (within the body) and ex vivo gene editing (in cells outside the body) to develop new medicines.

As of December 31, 2023, the company held 31 U.S. patents, 74 pending U.S. non-provisional patent applications, 16 European patents, 62 pending European patent applications, four U.S. provisional applications, nine PCT applications, and additional patent filings globally related to CRISPR technology.

Financial Highlights (FY 2025)

Company's Business Segments

• Gene editing technology : It offers gene editing technology to deliver transformative therapies that simplify the usability for patients, minimize the burdens to patients and healthcare systems, and are meaningfully differentiated from the current standards of care, while also allowing a simple, scalable manufacturing process to reduce costs to manufacture and administer the therapies.